SCHEMBL3405017

SCHEMBL3405017

COc1cccc(C(=O)Nc2nc3ccc(F)cc3s2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 9/20 0.83
KMT2A Q03164 6/20 0.76
NPC1 O15118 5/20 0.76
RAB9A P51151 5/20 0.76
MEN1 O00255 5/20 0.76
DHODH Q02127 1/20 0.76
LRRK2 Q5S007 2/20 0.71
HCRTR1 O43613 1/20 0.69
MAPT P10636 2/20 0.64
LMNA P02545 2/20 0.64
TP53 P04637 2/20 0.64
HTT P42858 1/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
HPGD P15428 1/20 0.60
ALOX15 P16050 1/20 0.60
TSHR P16473 1/20 0.60
ALOX12 P18054 1/20 0.60
HSD17B10 Q99714 1/20 0.60
SENP7 Q9BQF6 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12199358 0.91 SCD (0.83) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL12199328 0.91 SCD (0.83) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL4917247 0.91 SCD (0.83) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL31065 0.91 SCD (1.00) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL16742048 0.88 SCD (0.85) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL24729342 0.87 SCD (0.83) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL29947567 0.87 SCD (0.83) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL13561185 0.87 SCD (0.83) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL4916511 0.86 NPC1 (1.00) SCDKMT2ANPC1RAB9AMEN1
SCHEMBL2480611 0.85 SCD (1.00) SCDKMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-9433610-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2016-09-06 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
US-20150157607-A1 Compounds that Enhance Atoh1 Expression MASSACHUSETTS EYE & EAR INFIRMARY 2015-06-11 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2025-03-27 US disclosed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 SCD 3715/4885KMT2A 1792/4885NPC1 1607/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 SCD 4344/4885KMT2A 2721/4885NPC1 1630/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 SCD 4345/4885KMT2A 3575/4885NPC1 1011/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 SCD 3643/4885KMT2A 4253/4885NPC1 1656/4885
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS HES1, NOTCH1, NOTCH4 SCD 3643/4885KMT2A 4253/4885NPC1 1656/4885
US-20150157607-A1 Compounds that Enhance Atoh1 Expression DACH1, EZH1, CREBBP SCD 4080/4885KMT2A 514/4885NPC1 1018/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 SCD 4212/4885KMT2A 3639/4885NPC1 966/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP SCD 4080/4885KMT2A 514/4885NPC1 1018/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 SCD 3715/4885KMT2A 1792/4885NPC1 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.